Successful single-dose teicoplanin prophylaxis against experimental streptococcal, enterococcal, and staphylococcal aortic valve endocarditis

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1916-1921

  Perdikaris, George S ^a   Pefanis, Angelos ^b   Giamarellou, Helen ^a   Nikolopoulos, Athanasios ^a   Margaris, Elias P ^c   Donta, Ismini ^a   Tsitsika, Artemis ^a   Karayiannakos, Panayiotis ^a  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c KAT HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; TEICOPLANIN; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; AORTA VALVE; ARTICLE; BACTERIAL ENDOCARDITIS; DOSE RESPONSE; DRUG EFFICACY; ENTEROCOCCUS FAECALIS; FEMALE; INFECTION PREVENTION; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS ORALIS;

EID: 0030773095     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1916     Document Type: Article

References (39)

1. Anhalt, J. P. 1985. Assays for antimicrobial agents in body fluids, p. 1009-1014. In E. H. Lennette, A. Balows, W. J. Hausler, Jr., and H. J. Shadomy (ed.), Manual of clinical microbiology, 4th ed. American Society for Microbiology, Washington, D.C.
2. Bayer, A. S., and J. Tu. 1990. Chemoprophylactic efficacy against experimental endocarditis caused by β-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob. Agents Chemother. 34:1068-1074.
3. Bernard, J. P., P. Francioli, and M. P. Glauser. 1981. Vancomycin prophylaxis of experimental Streptococcus sanguis endocarditis: inhibition of bacterial adherence rather than bacterial killing. J. Clin. Invest. 68:1113-1116.
4. Calain, P., and F. Waldwogel. 1990. Clinical efficacy of teicoplanin. Eur. J. Clin. Microbiol. Infect. Dis. 9:127-129.
5. Campoli-Richards, D. M., R. N. Brogden, and D. Faulds. 1990. Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 40:449-486.
6. Chambers, H. F., and S. Kennedy. 1990. Effects of dosage, peak and trough concentrations in serum protein binding, and bactericidal rate of efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob. Agents Chemother. 34:510-514.
7. Cremieux, A. C., B. Maziere, J. M. Vallois, M. Ottaviani, A. Azancot, H. Raffoul, A. Bouret, J. J. Pocidalo, and C. Carbon. 1989. Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J. Infect. Dis. 159:938-944.
8. Dajani, A. S., A. L. Bisno, K. J. Chung, D. T. Durack, M. Freed, M. A. Gerber, A. W. Karchmer, H. D. Millard, S. Rahimtoola, S. T. Shulman, C. Watanakunakorn, and K. A. Taubert. 1990. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 264: 2919-2922.
9. Durack, D. T. 1995. Prevention of infective endocarditis. N. Engl. J. Med. 332:38-44.
10. Eliopoulos, G. M. 1993. Increasing problems in the therapy of enterococcal infections. Eur. J. Clin. Microbiol. Infect. Dis. 12:409-412.
11. Entenza, J. M., T. Calandra, Y. Moosmann, R. Malinverni, and M. P. Glauser. 1992. Teicoplanin versus vancomycin for prophylaxis of experimental Enterococcus faecalis endocarditis in rats. Antimicrob. Agents Chemother. 36:1256-1262.
12. Freedman, L. R. 1993. Editorial response: to prevent or not to prevent bacterial endocarditis. Clin. Infect. Dis. 17:195-197.
13. Glauser, M. P., J. P. Bernard, P. Moreillon, and P. Francioli. 1983. Successful single-dose prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection. J. Infect. Dis. 147:568-575.
14. Glauser, M. P., and P. Francioli. 1987. Relevance of animal models to the prophylaxis of infective endocarditis. J. Antimicrob. Chemother. 20(Suppl. A):87-93.
15. Hall, G., S. A. Hedstrom, A. Heimdahl, and C. E. Nord. 1993. Prophylactic administration of penicillins for endocarditis does not reduce the incidence of postextraction bacteremia. Clin. Infect. Dis. 17:188-194.
16. Hess, J., J. Dankert, and D. Durack. 1983. Significance of penicillin tolerance in vivo: prevention of experimental Streptococcus sanguis endocarditis. J. Antimicrob. Chemother. 11:555-564.
17. Malinverni, R., J. Bille, and M. P. Glauser. 1987. Single-dose rifampin prophylaxis for experimental endocarditis induced by high bacterial inocula of viridans streptococci. J. Infect. Dis. 156:151-157.
18. Medical Letter on Drugs. 1989. Prevention of bacterial endocarditis. Med. Lett. Drug 31:112.
19. Mini, E., T. Mazzei, E. F. Reali, A. Novelli, and P. Periti. 1989. Pharmacokinetics of teicoplanin during cardiopulmonary bypass surgery. Int. J. Clin. Pharmacol. Res. 9:287-292.
20. Moellering, R. C. 1992. Emergence of enterococcus as a significant pathogen. Clin. Infect. Dis. 14:1173-1178.
21. Moreillon, P., P. Francioli, D. Overholser, P. Meyland, and M. P. Glauser. 1986. Mechanisms of successful amoxicillin prophylaxis of experimental endocarditis due to Streptococcus intermedius. J. Infect. Dis. 154:801-807.
22. Perdikaris, G., H. Giamarellou, A. Pefanis, I. Donta, and P. Karayiannakos. 1995. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob. Agents Chemother. 39:2289-2294.
23. 22a. Perdikaris, G., A. Pefanis, P. Karayiannakos, A. Nikolopoulos, I. Donta, and H. Giamarellou. 1994. Successful single-dose teicoplanin (TE) prophylaxis against experimental streptococcal and enterococcal endocarditis due to tolerant strains, abstr. B69. p. 149. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Perlman, B. B., and L. R. Freedman. 1971. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J. Biol. Med. 44:206-221.
25. Polk, R. E. 1991. Anaphylactoid reactions to glycopeptide antibiotics. J. Antimicrob. Chemother. 27(Suppl. B):17-29.
26. Pujadas, R., E. Escriva, J. Jane, J. Argimon, F. Fernadez, P. Fava, M. Galera, and J. Garau. 1990. Tolerance and efficacy of parenterally administered penicillin-streptomycin and orally administered amoxicillin or penicillin V for prophylaxis of experimentally induced streptococcal endocarditis. Antimicrob. Agents Chemother. 34:321-325.
27. Roberts, R. B. 1992. Streptococcal endocarditis: the viridans and beta hemolytic streptococci, p. 191-208. In D. Kaye (ed.), Infective endocarditis, vol 2, 2nd ed. Raven Press, New York, N.Y.
28. Rowland, M. 1990. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 18:184-209.
29. Schaad, H. J., C. Chuard, F. A. Vaudaux, F. A. Waldvogel, and D. P. Lew. 1994. Teicoplanin alone or combined with rifampin compared with vancomycin for prophylaxis and treatment of experimental foreign body infection by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 38:1703-1710.
30. Scheld, W. M., and M. A. Sande. 1990. Endocarditis and intravascular infections, p. 670-706. In G. L. Mandell, R. G. Douglas, and R. Dolin (ed.), Principles and practice of infectious diseases, 3rd ed. Churchill Livingstone, New York, N.Y.
31. Scheld, W. M., O. Zak, K. Vosbeck, and M. A. Sande. 1981. Bacterial adhesion in the pathogenesis of infective endocarditis: effect of sub-inhibitory antibiotic concentrations on streptococcal adhesion in vitro and the development of endocarditis in rabbits. J. Clin. Invest. 68:1381-1384.
32. Shanson, D. C., A. Shehata, M. Tadayon, and M. Harris. 1987. Comparison of intravenous teicoplanin with intramuscular amoxycillin for the prophylaxis of streptococcal bacteremia in dental patients. J. Antimicrob. Chemother. 20:85-93.
33. Somma, S., L. Gastaldo, and A. Corti. 1984. Teicoplanin, a new antibiotic from Actinoplanes teichomyceticus nov. sp. Antimicrob. Agents Chemother. 26:917-923.
34. Van der Meer, J. T. M., W. van Vianen, E. Hu, W. B. van-Leeuwen, H. A. Valkenburg, J. Thompson, and M. F. Michel. 1991. Distribution, antibiotic susceptibility and tolerance of bacterial isolates in culture-positive cases of endocarditis in The Netherlands. Eur. J. Clin. Microbiol. Infect. Dis. 10:728-734.
35. Verbist, L., B. Tjandramaga, B. Hentrickx, A. van-Hecken, P. van-Melle, R. Verbesselt, J. Verhaegen, and P. J. De Schepper. 1984. In vitro activity and human pharmacokinetics of teicoplanin. Antimicrob. Agents Chemother. 26:881-886.
36. Voorn, G. P., J. Kuyvenhoven, W. H. F. Goessens, S. Schmall, W. C. Bauer, P. H. Broeders, J. Thompson, and M. F. Michel. 1994. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin and daptomycin. Antimicrob. Agents Chemother. 38:487-493.
37. Voorn, G. P., J. Thompson, W. H. F. Goessens, W. C. Schmall-Bauer, P. H. M. Broeders, and M. F. Michel. 1992. Role of tolerance in cloxacillin prophylaxis of experimental Staphylococcus aureus endocarditis. J. Infect. Dis. 166:169-173.
38. Wilson, A. P. R., and R. N. Gruneberg. 1994. Use of teicoplanin in community medicine. Eur. J. Clin. Microbiol. Infect. Dis. 13:701-710.
39. Working Party of the British Society for Antimicrobial Chemotherapy. 1990. Antibiotic prophylaxis of infective endocarditis. Lancet 335:88-89.